Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07220060 in Advanced Solid Tumors
NCT04557449Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of atirmociclib in breast cancer, prostate cancer (PCa), non-small cell lung cancer (NSCLC) and 3 more (14 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 24 months and 3 more. Started Sep 2020; status: recruiting.
02
Drugs
atirmociclib
03
Conditions
breast cancerprostate cancer (PCa)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)Liposarcoma
Beyond the preview
Go deeper on NCT04557449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557449.